Our Location

304 North Cardinal St.
Dorchester Center, MA 02124

Upadacitinib15mg-Rematib | Skin Cancer Medication

Product Name: Rematib

Generic Name: Upadacitinib

Strength: 15mg

Volume: 30 tablets

Manufacturer: Drug International

Whats app & We Chat: +8801304498958

WeChat QR
WeChat QR

Upadacitinib15mg-Rematib: A medication guide for adults and children 12+ with moderate to severe inflammatory conditions like skin cancers, rheumatoid arthritis, and more.


Upadacitinib15mg-Rematib is used to treat rheumatoid arthritis in people who are unable to take other medications. And have not responded to tumor necrosis factor inhibitors. It is used to treat psoriatic arthritis, eczema, and ulcerative colitis.

  • Upadicitnib is a Janus kinase inhibitor. It works by decreasing the activities of the immune system.
  • Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and DMARD. Which is used to slow down the progression of rheumatoid arthritis. That is a chronic autoimmune inflammatory disease affecting peripheral joints.
  • Despite various treatments, up to 40% of patients do not respond to current therapies. The role of JAK in immune-mediated conditions led to the development of more selective JAK1 inhibitors, upadacitinib and filgotinib.
  • FDA approved Upadacitinib in August 2019. RINVOQ is the brand name of Upadacitinib and this is an oral medication.

Worried about skin cancers or struggling with active ankylosing spondylitis?

Rematib (upadacitinib15mg) may be the answer. This medication guide dives into Rematib, highlighting its potential benefits and crucial considerations for various conditions. [1]


  • Upadacitinib15mg-Rematib is a medication used to treat moderately active rheumatoid arthritis or psoriatic arthritis in adults. Who has had an inadequate response to disease-modifying anti-rheumatic drugs (DMARDs)?
  • On the other hand It is also used in patients aged 12 and older with refractory, moderate-to-severe atopic dermatitis. Moreover to treat active ankylosing spondylitis or radiographic axial spondyloarthritis.
  • In addition, non-radiographic axial spondyloarthritis with objective signs of inflammation. Moderately to severely active ulcerative colitis, and moderately to severely active Crohn’s disease. Doctors do not recommend upadacitinib with other JAK inhibitors, biologic DMARDs, or other potent immunosuppressive agents.

Mechanism of Action

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease involving immune cells and pro-inflammatory cytokines.

The Janus Kinase (JAK) family. Which consist of four isoforms and play a crucial role in normal physiological functions and the signaling of pro-inflammatory cytokines.

  1. JAK1 is primarily involved in the signaling transduction pathways of IL-6, IFN, and common γ-chain cytokines.
  2. JAKs mediate the JAK-STAT signal transduction pathway, which promotes pro-inflammatory events such as increased proliferation and survival of immune cells. T cell differentiation, and macrophage activation.
  3. Upadacitinib, a selective JAK1 inhibitor, has been shown to block cellular processes contributing to RA inflammatory conditions. In human leukocyte cellular assays, upadacitinib inhibited JAK1/3-induced phosphorylation of STAT3/5 mediated by IL-6/7.


Upadacitinib15mg-Rematib has a dose-proportional pharmacokinetic profile, reaching Cmax within 2 to 4 hours after oral administration. Its steady-state plasma concentrations are reached within 4 days after multiple daily administrations, with minimal accumulation. Food intake doesn’t affect its AUC, Cmax, and Cmin.

Dosage and Administrations

Upadacitinib15mg is an oral medication available in 15mg, 30mg, and 45mg extended-release tablets, prescribed for:

  • Adults and children 12 years and older (weighing at least 40kg) with moderate to severe atopic dermatitis (eczema) not controlled by other therapies.
  • Adults with moderately to severely active rheumatoid arthritis who haven’t responded well to or can’t tolerate one or more TNF blockers.
  • Adults with active psoriatic arthritis who haven’t responded well to or can’t tolerate one or more TNF blockers.
  • Adults with active ankylosing spondylitis who haven’t responded well to or can’t tolerate one or more TNF blockers.
  • Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who haven’t responded well to or can’t tolerate a TNF blocker.
  • Adults with moderately to severely active ulcerative colitis or Crohn’s disease who haven’t responded well to or can’t tolerate one or more conventional therapies.

Side Effects and Risks

Before considering Upadacitinib15mg, understand the potential risks:

  • Increased risk of serious infections: Talk to your doctor about past infections and vaccinations before starting Upadacitinib15mg.
  • Allergic reactions: Stop taking Upadacitinib15mg and seek immediate medical attention. Furthermore, if you experience severe allergic reactions.
  • In addition Other potential side effects are headache, nausea, fatigue, and high blood pressure with your doctor.

Remember, Upadacitinib15mg is not for everyone.

Discuss your medical history, allergies, and current medications with your doctor. The doctor will determine if Upadacitinib15mg is right for you. This guide provides a starting point, but personalized medical advice is crucial.

Take control of your health. Talk to your doctor about Upadacitinib15mg today. Then see if it can help you manage your condition and reclaim your life.

Here are some FAQs about upadacitinib

How to use Upadacitinib15mg-Rematib?

Upadacitinib comes as an extended-release tablet. It is usually taken by mouth with or without food once a day. According to your prescription.

Do not take more or less. it may cause side effects for you.

Follow the prescription carefully and ask your doctor or pharmacist if you do not understand any part of the prescription.

What is the effectiveness of Upadacitinib15mg-Rematib?

Patients who have received Upadacitinib-15mg or Rematib-15 mg got significant results by 12/14 weeks. It is a beneficial medication for treating rheumatoid arthritis, Psoriatic arthritis, and ulcerative colitis.

What are the side effects of using Upadacitinib15mg-Rematib?

There are a few common side effects of using Rematib-15mg like stuffy or runny nose, nausea, headache, weight gain, etc.

How to order Upadacitinib15mg-Rematib?

Ordering any medicine from our website is very easy. We attach our contact info with the product image, anyone can reach us by that contact info. Or you may go to our Contact Us page and then send us a text referring to your query like which medicine you want to purchase, how many quantities of the product you want, which shipping method you would prefer, etc. Simply tell us the medicine name, medicine quantity, where to send I mean the country name, your mailing address. For any kind of query, you may mail us, or send a text message through Whats app, or WeChat at +8801304498958 this number.

See our other products Baricinix 4mg, Rutinib Cream, Tofanib

Q: What is Upadacitinib15mg?

A: Upadacitinib15mg is a medication that contains the active ingredient Upadacitinib. It belongs to a class of drugs known as Janus kinase (JAK) inhibitors.

Q: How does Upadacitinib15 mg work?

A: Rematib 15 mg (Upadacitinib) works by blocking specific enzymes called Janus kinases, which are involved in the signaling pathways of certain immune cells. Inhibiting these enzymes helps reduce inflammation and control the immune response in conditions like rheumatoid arthritis and other related diseases.

Q: Are there any side effects of Rematib 15 mg?

A: Like any medication, Rematib 15 mg (Upadacitinib) may cause side effects. Common side effects may include upper respiratory tract infections, nausea, diarrhea, headache, and increased blood cholesterol levels. It is important to discuss any potential side effects with your doctor.

Q: Can Rematib 15 mg be used during pregnancy or breastfeeding?

A: The use of Rematib 15 mg (Upadacitinib) during pregnancy or breastfeeding should be discussed with your doctor. It is important to weigh the potential benefits against the potential risks before using this medication in these situations.






There are no reviews yet.

Be the first to review “Upadacitinib15mg-Rematib | Skin Cancer Medication”